Quarterly ResultAug 11, 2026, 04:04 PM
Maze Therapeutics Reports Q2 Results; Clinical Trials Advance, Cash $495M
AI Summary
Maze Therapeutics reported Q2 2026 financial results and provided updates on its clinical pipeline. The company announced that enrollment in the Phase 2 HORIZON trial of MZE829 is on track, with data expected in late 2026 or early 2027. The Phase 2 CIPheR trial of MZE782 in PKU has been initiated, with topline data anticipated in 2027, and a Phase 2 trial for MZE782 in CKD is set to begin in H1 2027. Maze maintains a strong balance sheet with $494.9 million in cash, cash equivalents, and marketable securities, extending its expected cash runway into 2029.
Key Highlights
- MZE829 Phase 2 HORIZON trial data from all cohorts expected late 2026 or early 2027.
- MZE782 Phase 2 CIPheR trial in PKU initiated, topline data expected in 2027.
- MZE782 Phase 2 trial in CKD on track for H1 2027 initiation.
- Cash, cash equivalents, and marketable securities totaled $494.9 million as of June 30, 2026.
- Expected cash runway into 2029 based on current business plan.
- Net loss for Q2 2026 was $44.7 million, or $0.76 per share.
- R&D expenses for Q2 2026 increased to $34.9 million from $28.1 million in Q2 2025.
- G&A expenses for Q2 2026 increased to $13.1 million from $8.4 million in Q2 2025.
Price Impact
More from MAZE